Bio
Dr. Craig?s research interests center on examining the roles of incretin hormones in glucose metabolism, and the development and application of incretin-targeted therapies for improved glucose homeostasis. In particular, Dr. Craig?s clinical research focuses on the incretin gut hormone glucagon-like peptide-1 and its role in mediating hyperinsulinemic hypoglycemia conditions, including post-bariatric hypoglycemia (PBH). Ongoing investigations further examine potential mechanisms mediating PBH, as well as the cognitive, cardiovascular, and quality of life implications of recurrent severe hypoglycemia. Dr. Craig obtained her M.D. at Brown University School of Medicine and completed her postdoctoral research fellowship at Stanford University School of Medicine in the lab of Dr. Tracey McLaughlin.
Honors & Awards
-
NIH KL2 Mentored Career Development Award, National Institutes of Health (2014)
-
TRAM Fellow Pilot Award, Stanford Translational and Applied Medicine (TRAM) Program (2014)
-
SPARK Award (Co-Investigator), Stanford SPARK Program (2015)
-
TRAM Fellow Pilot Award, Stanford Translational and Applied Medicine (TRAM) Program (2015)
Boards, Advisory Committees, Professional Organizations
-
Co-Founder, President, Foundation for Post-Bariatric Surgery Hypoglycemia (2014 - Present)
-
Member, American Diabetes Association (2014 - Present)
-
Member, Endocrine Society (2014 - Present)
Professional Education
-
MD, Brown University School of Medicine, Medicine (2006)
-
Bachelor of Arts, Tufts University, English (1995)
Patents
-
Colleen Craig. " Patent WO 2016/191394 Treatment of Post?Bariatric Hypoglycemia With GLP?1 Antagonists", Leland Stanford Junior University
-
Colleen Craig. " Patent WO 2016/191395 Treatment of Post?Bariatric Hypoglycemia With Exendin(9?39)", Leland Stanford Junior University
-
Colleen Craig. " Patent WO2018094404 Buffered Formulations of Exendin (9?39)", Leland Stanford Junior University, Eiger BioPharmaceuticals